You are here

Injectable Foam to Staunch Bleeding is Breakthrough Therapy

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma

Life Foam™, an expanding, internal-use injectable hemostat, designed by gel-e Inc., has received a breakthrough status designation from the FDA.

Life Foam provides rapid, temporary control of bleeding from non-compressible abdominal wounds that do not lend themselves to tourniquet application during trauma and battlefield conditions. The product is designed to save the lives of those injured in battle, or who are victims of traumatic accidents or terrorist attacks.

Trauma from accidents is the third leading cause of death in the U.S. after heart disease and cancer. Approximately 85% of all hemorrhage-related deaths arise from non-compressible internal bleeding––intracavitary (e.g., abdominal) bleeding that is not accessible to direct pressure and cannot be controlled by typical methods such as gauze or a tourniquet.

When it is delivered into the abdominal cavity, Life Foam expands dramatically, seeking out the bleeding source in the patient for quick and efficient stabilization. This enables the injured person to be safely transported to a trained trauma surgeon, who can repair the damage in a controlled surgical environment.

The foam is currently in preclinical development for treating patients who have been injured in battlefield conditions or where life-threatening internal bleeding occurs in a location away from immediate urgent care.

Source: BioSpace, June 18, 2019

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug